BBIO Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -4506.12% compared to BridgeBio Pharma's net margin of 39.44%. BridgeBio Pharma's return on equity of -- beat Catalyst Pharmaceuticals's return on equity of 27.81%.

BridgeBio Pharma has a consensus price target of $53.82, signalling upside risk potential of 63%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 41.62%. Given that BridgeBio Pharma has higher upside potential than Catalyst Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Catalyst Pharmaceuticals.

BridgeBio Pharma has a beta of 1.078, which suggesting that the stock is 7.822% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $5.9M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. BridgeBio Pharma's net income of -$265.1M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 18.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 27.69x versus 6.08x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -4506.12% compared to BridgeBio Pharma's net margin of -225.53%. BridgeBio Pharma's return on equity of -- beat Insmed's return on equity of -41989.34%.

BridgeBio Pharma has a consensus price target of $53.82, signalling upside risk potential of 63%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 32.62%. Given that BridgeBio Pharma has higher upside potential than Insmed, analysts believe BridgeBio Pharma is more attractive than Insmed.

BridgeBio Pharma has a beta of 1.078, which suggesting that the stock is 7.822% more volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $5.9M, which are smaller than Insmed quarterly revenues of $104.4M. BridgeBio Pharma's net income of -$265.1M is lower than Insmed's net income of -$235.5M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 27.69x versus 32.47x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -4506.12% compared to BridgeBio Pharma's net margin of 2.31%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 8.91%.

BridgeBio Pharma has a consensus price target of $53.82, signalling upside risk potential of 63%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 27.38%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

BridgeBio Pharma has a beta of 1.078, which suggesting that the stock is 7.822% more volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.89% to investors and pays a quarterly dividend of $0.43 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $5.9M, which are smaller than Pfizer quarterly revenues of $17.8B. BridgeBio Pharma's net income of -$265.1M is lower than Pfizer's net income of $410M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 27.69x versus 2.20x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -4506.12% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Plus Therapeutics's return on equity of --.

BridgeBio Pharma has a consensus price target of $53.82, signalling upside risk potential of 63%. On the other hand Plus Therapeutics has an analysts' consensus of $9.38 which suggests that it could grow by 819.12%. Given that Plus Therapeutics has higher upside potential than BridgeBio Pharma, analysts believe Plus Therapeutics is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.078, which suggesting that the stock is 7.822% more volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.459%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $5.9M, which are larger than Plus Therapeutics quarterly revenues of --. BridgeBio Pharma's net income of -$265.1M is lower than Plus Therapeutics's net income of -$2.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 27.69x versus 1.12x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.